Sydnexis Inc. is focused on decreasing myopic progression in children. The company offers a novel, stable, and comfortable topical eyedrop used once daily at bedtime, supported by a Phase 3 study.

Sydnexis

Sydnexis Inc.

Sydnexis | 1,114 followers on LinkedIn. We focus on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic. | Myopia is the most common eye disease in children and has
experienced a dramatic increase in prevalence over the last 30 years.
Once considered a benign refractive condition, even at low levels,
myopia is now associated with many serious ophthalmic co-
morbidities. The greater myopia severity, the higher the risk of these
ophthalmic co-morbidities later in life.

Zach Scheiner

Vice President, Manufacturing at Sydnexis

Kenneth Laderman, Ph.D.

Sr. Director, Project Management at Sydnexis

Timothy Murphy, MS

Chief Commercial Officer, Sydnexis

Nick Ruth

At the 2024 ARVO meeting, there were a number of groundbreaking myopia posters and papers. Review of Myopia Management ’s article does a great job of collecting the studies of interest for myopia. Pay close attention to article #20, The Projection of Glaucoma Burden Worldwide in 2060 with Myopia Surge. Truly shocking forecast. https://lnkd.in/e5pvTUNJ #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #glaucoma

Compared with low and moderate myopia, patients with a high degree of myopia experienced impaired quality of life similar to that of patients with keratoconus. #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

Discover the dynamic individuals who power Sydnexis forward. Today we spotlight Kenneth Laderman, Ph.D. Click here to watch the video! https://lnkd.in/gSmD7vB3

Global Myopia Rates in Children and Teens Expected to Surpass 740 Million by 2050. https://lnkd.in/dy3ybvEh #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

National Academies of Sciences, Engineering, and Medicine’s, recently published, Consensus Study Report on Myopia recommends CMS to classify Myopia as a Disease (Recommendation 8-5). https://lnkd.in/eXCBYjFe #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

National Geographic is spotlighting the concerning rise of myopia worldwide. https://lnkd.in/e-jK2AmG #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

Alert! One in Three Children worldwide are now Myopic. https://lnkd.in/d2hmBRFm #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

Post-Myopic Maculopathy: What Is It and How Is It Treated? Preventing moderate-to-severe myopia is vital, to minimize the risk of developing of pathological myopia. Efforts to target myopia awareness and the management of myopia progression in childhood are imperative. Read the article - https://lnkd.in/eZkKUqcx #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy

Do Not wait to begin myopia treatment. Study reinforces the immense importance of starting myopia treatment as soon as possible, because every diopter lost can never be recovered. #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

The Economic Burden of Vision Impairment is Great. Costs differences, over the lifetime of a patient, are dramatic compared to non-vision impaired individuals. #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #eyecarecost #visionimpairment

SYDN

COM:SYDNEXIS

Sydnexis Inc.

locale

market

industry

website

crunchbase

linkedin

peer of

Metrics